JP2011528030A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528030A5
JP2011528030A5 JP2011518009A JP2011518009A JP2011528030A5 JP 2011528030 A5 JP2011528030 A5 JP 2011528030A5 JP 2011518009 A JP2011518009 A JP 2011518009A JP 2011518009 A JP2011518009 A JP 2011518009A JP 2011528030 A5 JP2011528030 A5 JP 2011528030A5
Authority
JP
Japan
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011518009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528030A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2009/050856 external-priority patent/WO2010007427A1/en
Publication of JP2011528030A publication Critical patent/JP2011528030A/ja
Publication of JP2011528030A5 publication Critical patent/JP2011528030A5/ja
Pending legal-status Critical Current

Links

JP2011518009A 2008-07-16 2009-07-15 ピリミジルスルホンアミド誘導体およびケモカイン介在疾患処置のためのその使用 Pending JP2011528030A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8121308P 2008-07-16 2008-07-16
US61/081,213 2008-07-16
PCT/GB2009/050856 WO2010007427A1 (en) 2008-07-16 2009-07-15 Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases

Publications (2)

Publication Number Publication Date
JP2011528030A JP2011528030A (ja) 2011-11-10
JP2011528030A5 true JP2011528030A5 (enExample) 2012-08-30

Family

ID=41011976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011518009A Pending JP2011528030A (ja) 2008-07-16 2009-07-15 ピリミジルスルホンアミド誘導体およびケモカイン介在疾患処置のためのその使用

Country Status (13)

Country Link
US (1) US20100016275A1 (enExample)
EP (1) EP2315754A1 (enExample)
JP (1) JP2011528030A (enExample)
KR (1) KR20110031462A (enExample)
CN (1) CN102159555A (enExample)
AR (1) AR072818A1 (enExample)
AU (1) AU2009272425B2 (enExample)
BR (1) BRPI0915908A2 (enExample)
CA (1) CA2730477A1 (enExample)
MX (1) MX2011000402A (enExample)
RU (1) RU2011101661A (enExample)
TW (1) TW201006824A (enExample)
WO (1) WO2010007427A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007002240A (es) * 2004-08-28 2007-04-20 Astrazeneca Ab Derivados de pirimidinosulfonamida como moduladores del receptor quimiocina.
SG186859A1 (en) 2010-07-13 2013-02-28 Astrazeneca Ab New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
PE20181069A1 (es) 2011-07-12 2018-07-04 Astrazeneca Ab N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina
JP6096808B2 (ja) * 2012-02-07 2017-03-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規なアゼチジン誘導体
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
AU2017231832B2 (en) 2016-03-11 2021-11-11 Ardea Biosciences, Inc. CXCR-2 inhibitors for treating crystal arthropathy disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540356A (en) * 1949-03-12 1951-02-06 Sharp & Dohme Inc Sulfonamide derivatives
GB866843A (en) * 1958-12-08 1961-05-03 Ici Ltd Sulphonamidopyrimidines
NL279406A (enExample) * 1961-06-16
NL302745A (enExample) * 1962-12-29
US3457278A (en) * 1964-10-15 1969-07-22 Geigy Chem Corp Cyclopropyl-4-sulfanilamido-pyrimidines
US3452018A (en) * 1966-08-29 1969-06-24 American Home Prod 1 - (2 - substituted - 6 - arylsulfonamidopyrimidin - 4 - yl)pyridinium hydroxide inner salts
US3673184A (en) * 1970-09-02 1972-06-27 Dainippon Pharmaceutical Co Certain 2-substituted-5,8-dihydro-5-oxopyrido{8 2,3-d{9 pyrimidine-6-carboxylic acid derivatives
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
ATE381546T1 (de) * 2002-08-24 2008-01-15 Astrazeneca Ab Pyrimidinderivate als modulatoren der aktivitut von chemokinrezeptoren
GB0401269D0 (en) * 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
GB0419235D0 (en) * 2004-08-28 2004-09-29 Astrazeneca Ab Compounds
MX2007002240A (es) * 2004-08-28 2007-04-20 Astrazeneca Ab Derivados de pirimidinosulfonamida como moduladores del receptor quimiocina.
JP2006137723A (ja) * 2004-11-15 2006-06-01 Kyowa Hakko Kogyo Co Ltd スルホンアミド誘導体

Similar Documents

Publication Publication Date Title
TWI483941B (zh) 流感病毒複製之抑制劑
JP2011528030A5 (enExample)
JP2013542261A5 (enExample)
TW202417442A (zh) 苯甲醯胺化合物
JP2014524442A5 (enExample)
JP2013519645A5 (enExample)
HRP20161696T4 (hr) Tenofovir alafenamid hemifumarat
JP2011528658A5 (enExample)
CA3023216A1 (en) Compounds and compositions for inhibiting the activity of shp2
CN1227233C (zh) 纯晶形的5-氯-3-(4-甲磺酰基苯基)-6′-甲基-[2,3′]联吡啶及其合成方法
JP2015522028A (ja) 化合物とその治療用途
MX2015004787A (es) Compuestos antiviricos para el virus sincitial respiratorio.
WO2013151708A1 (en) Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
CN103249697A (zh) 适用作多巴胺能稳定剂的普利多匹定(pridopidine)氘化类似物
JP2006504766A5 (enExample)
JP2020536893A5 (enExample)
JP2014525470A5 (enExample)
JP2017531619A5 (enExample)
EA009941B1 (ru) Имидазопиридинзамещённые тропановые производные, обладающие активностью антагониста ccr5 рецептора, для лечения вируса иммунодефицита человека (вич) и воспаления
RU2022109286A (ru) Кристаллическая форма гидрата свободного основания лорлатиниба
JP2012533550A5 (enExample)
EP3642195A1 (en) Substituted 5-cyanoindole compounds and uses thereof
JP2015522018A5 (enExample)
CN116406355A (zh) P38α促分裂原活化蛋白激酶抑制剂
CN101531653B (zh) 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用